Seasonal changes and decrease of suicides and suicide attempts in France over the last 10 years.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 05 2022
Historique:
received: 29 10 2021
accepted: 26 04 2022
entrez: 17 5 2022
pubmed: 18 5 2022
medline: 20 5 2022
Statut: epublish

Résumé

The objective of this study was to examine the evolution of suicides and suicide attempts over the last 10 years in France. We analyzed the number of deaths by suicide and suicide attempts in metropolitan France (2009-2018) from French national databases, on a daily, weekly or monthly basis. Seasonal variation in suicide rates was modeled using a cosinor function. Based on this model, we determined the association of suicides and suicide attempts with geographic characteristics, age, gender, means used and psychiatric disorders. The number of suicides and suicide attempts decreased over the last ten years in France (mean decrease of 14.49% and 11.69% per year). We observed a significant and recurrent seasonal pattern of suicides and suicide attempts in France, with a peak in spring. The suicide and suicide attempt rates were higher in the northern departments of France. Suicides were more frequent for men (75%) and middle-age individuals (45-54 years old), while suicide attempts were more frequent for women (62%) and young adults and middle-age individual (15-19 and 40-49 years old). Nearly two-thirds of the patients who attempted suicide suffered from comorbid psychiatric disorders. Mood disorders was the most frequent comorbid psychiatric disorder (54%). Voluntary drug intoxication was the most common means of suicide attempt (80%), and hanging was the most common means of suicide (54%). The number of suicides and suicide attempts decreased in France over the last 10 years, with large and recurrent seasonal variations. These findings could be used to alert and adjust prevention policies, as well as developing preventive strategies such as chronotherapeutics.

Identifiants

pubmed: 35581322
doi: 10.1038/s41598-022-12215-3
pii: 10.1038/s41598-022-12215-3
pmc: PMC9114420
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8231

Informations de copyright

© 2022. The Author(s).

Références

Environ Health Perspect. 2019 Nov;127(11):117007
pubmed: 31769300
Neurobiol Dis. 2010 Mar;37(3):747-55
pubmed: 20034565
BMC Psychiatry. 2017 Nov 15;17(1):365
pubmed: 29141599
Encephale. 2015 Sep;41(4 Suppl 1):S29-37
pubmed: 26746320
Sci Total Environ. 2019 Jan 1;646:1021-1029
pubmed: 30235587
BMJ. 2019 Feb 6;364:l94
pubmed: 31339847
Epidemiol Psychiatr Sci. 2019 Jun 07;29:e39
pubmed: 31172899
Lancet. 2002 Dec 7;360(9348):1840-2
pubmed: 12480364
Arch Gen Psychiatry. 1995 Nov;52(11):937-46
pubmed: 7487342
BMC Psychiatry. 2020 Jan 28;20(1):26
pubmed: 31992251
Eur J Pharmacol. 2010 Mar 10;629(1-3):7-11
pubmed: 20004658
Environ Health Prev Med. 2013 Sep;18(5):349-55
pubmed: 23382022
Chronobiol Int. 2013 Nov;30(9):1101-7
pubmed: 23931033
N Engl J Med. 2020 Jan 16;382(3):266-274
pubmed: 31940700
Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1854-60
pubmed: 20505932
Am J Med Genet B Neuropsychiatr Genet. 2004 May 15;127B(1):48-50
pubmed: 15108179
Rev Epidemiol Sante Publique. 2013 Aug;61(4):363-74
pubmed: 23849295
Encephale. 1994 Sep-Oct;20(5):495-503
pubmed: 7828512
Environ Health Prev Med. 2014 Jul;19(4):286-94
pubmed: 24794752
Psychol Med. 2003 Apr;33(3):395-405
pubmed: 12701661
Am J Psychiatry. 2002 Jun;159(6):909-16
pubmed: 12042175
Am J Physiol Regul Integr Comp Physiol. 2012 May;302(9):R1049-58
pubmed: 22378771
Environ Health Prev Med. 2013 Nov;18(6):494-501
pubmed: 23835646
J Affect Disord. 2014 Oct;168:210-23
pubmed: 25063960
Psychol Med. 2022 Mar;52(4):707-714
pubmed: 32618240
Encephale. 2019 Jan;45 Suppl 1:S13-S21
pubmed: 30477899
Am J Emerg Med. 2003 Jul;21(4):271-5
pubmed: 12898481
J Affect Disord. 2013 May;147(1-3):17-28
pubmed: 23411024
Am J Psychiatry. 2017 Aug 1;174(8):765-774
pubmed: 28320225
J Public Health (Oxf). 2016 Sep;38(3):e282-e291
pubmed: 26503486
Epidemiol Psychiatr Sci. 2019 Oct 25;29:e63
pubmed: 31648654

Auteurs

Marine Ambar Akkaoui (M)

Département de Psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, 75018, Paris, France. marine.ambar@gmail.com.
Centre Psychiatrique d'Orientation et d'Accueil (CPOA), Hôpital Sainte Anne, GHU Paris Psychiatrie & Neurosciences, 1 Rue Cabanis, 75014, Paris, France. marine.ambar@gmail.com.
Etablissement Publique de Santé Mentale de Ville Evrard, 202 Avenue Jean Jaurès, Neuilly Sur Marne, France. marine.ambar@gmail.com.

Christine Chan-Chee (C)

Santé Publique France, 12 Rue du Val d'Osne, 94415, Saint-Maurice Cedex, France.

Karine Laaidi (K)

Santé Publique France, 12 Rue du Val d'Osne, 94415, Saint-Maurice Cedex, France.

Gregory Fifre (G)

Météo-France, Direction des Services de la Météorologie, Avenue G. Coriolis, 31057, Toulouse, France.

Michel Lejoyeux (M)

Département de Psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, 75018, Paris, France.
GHU Paris - Psychiatry & Neurosciences, 1 Rue Cabanis, 75014, Paris, France.

Guillaume Vaiva (G)

Univ Lille, INSERM U 1772, CHU Lille, General Psychiatry Department, Hôpital Fontan, 59037, Lille, France.
Centre National de Ressources et Résilience pour les Psychotraumatismes Cn2r Lille Paris, Lille, France.

Hugo Peyre (H)

Neurodiderot, INSERM UMR 1141, Paris Diderot University, Paris, France.
Department of Child and Adolescent Psychiatry, Robert Debré Hospital, APHP, Paris, France.

Pierre A Geoffroy (PA)

Département de Psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, 75018, Paris, France.
GHU Paris - Psychiatry & Neurosciences, 1 Rue Cabanis, 75014, Paris, France.
Université de Paris, NeuroDiderot, Inserm, 75019, Paris, France.
CNRS UPR 3212, Institute for Cellular and Integrative Neurosciences, 67000, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH